Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thrombolytic therapy with streptokinase using a standard dosage scheme.

Literature DB >> 5902682

Thrombolytic therapy with streptokinase using a standard dosage scheme.

M Verstraete, J Vermylen, A Amery, C Vermylen.

Abstract

Mesh：

Substances：
Streptokinase

Year: 1966 PMID： 5902682 PMCID： PMC1843663 DOI： 10.1136/bmj.1.5485.454

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

× No keyword cloud information.

13 in total

1. The streptokinase reactivity test. I. Standardization.

Authors: A AMERY; H MAES; J VERMYLEN; M VERSTRAETE
Journal: Thromb Diath Haemorrh Date: 1963-04-15

2. STUDIES ON THE ADMINISTRATION OF STREPTOKINASE. A METHOD FOR OBTAINING A THROMBOLYTIC EFFECT WITHOUT EXCESSIVE FIBRINOGENOLYSIS.

Authors: I HELLE
Journal: Acta Med Scand Date: 1963-09

3. [THROMBOLYTIC THERAPY. CLINICAL TRIALS OF TREATMENT WITH PURIFIED STREPTOKINASE].

Authors: M ABASTADO
Journal: Bull Mem Soc Med Hop Paris Date: 1964-07-03

4. [Comparative research on the streptokinase resistance test and a thromboelastographic streptokinase tolerance test].

Authors: A STACHER; J BOEHNEL
Journal: Schweiz Med Wochenschr Date: 1961-09-30

5. Treatment of peripheral arterial occlusion by streptokinase perfusion.

Authors: G P MCNICOL; W REID; W H BAIN; A S DOUGLAS
Journal: Br Med J Date: 1963-06-08

6. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test).

Authors: C VERMYLEN; R A DE VREKER; M VERSTRAETE
Journal: Clin Chim Acta Date: 1963-05 Impact factor: 3.786

7. [A contribution to fibrinolytic therapy with streptokinase and streptolysin].

Authors: W FISCHBACHER
Journal: Thromb Diath Haemorrh Date: 1961-12-15

8. [The effect of intravenously administered streptokinase on fibrinolysis and blood coagulation].

Authors: E DEUTSCH; M FISCHER
Journal: Thromb Diath Haemorrh Date: 1960-06-15

9. The intravascular use of streptokinase.

Authors: A J JOHNSON; A P FLETCHER; W R McCARTY; W S TILLETT
Journal: Ann N Y Acad Sci Date: 1957-08-30 Impact factor: 5.691

10. A technique for routine evaluation of plasminogen in humans during streptokinase therapy.

Authors: R A de Vreker
Journal: Acta Haematol Date: 1965-11 Impact factor: 2.195

24 in total

1. Thrombolytic treatment for recurrent myocardial infarction.

Authors: H White
Journal: BMJ Date: 1991-02-23

2. A rapid agglutination assay to detect anti-streptokinase antibodies.

Authors: J P McRedmond; N T Mulvihill; M Kane; B Burke; B Aloul; T Forde; M Walsh; D J Fitzgerald
Journal: Ir J Med Sci Date: 2004 Oct-Dec Impact factor: 1.568

Review 3. Is the development of antibodies to streptokinase clinically relevant?

Authors: M B Buchalter
Journal: Drugs Date: 1994-08 Impact factor: 9.546

Review 4. Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses.

Authors: R N Brogden; T M Speight; G S Avery
Journal: Drugs Date: 1973 Impact factor: 9.546

Review 5. Anticoagulant and thrombolytic drugs. I. Patho-physiological and pharmacological aspects.

Authors: D Ogston; A S Douglas
Journal: Drugs Date: 1971 Impact factor: 9.546

6. The problems of thrombosis in the deep veins of the leg.

Authors: V V Kakkar
Journal: Ann R Coll Surg Engl Date: 1969-11 Impact factor: 1.891

7. Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.

Authors: S Patel; S Jalihal; D P Dutka; G K Morris
Journal: Br Heart J Date: 1993-08

Review 8. Antithrombotic drugs: part II.

Authors: A S Gallus; J Hirsh
Journal: Drugs Date: 1976 Impact factor: 9.546

9. Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems.

Authors: J Hirsh; G S Hale; I G McDonald; R A McCarthy; A Pitt
Journal: Br Med J Date: 1968-12-21

Review 10. Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors: D M Lutomski; M Bottorff; K Sangha
Journal: Clin Pharmacokinet Date: 1995-01 Impact factor: 6.447